Are Myths and Preconceptions Preventing Us from Applying Ionic Liquid Forms of Antiviral Medicines to the Current Health Crisis?
At the moment, there are no U.S. Food and Drug Administration (U.S. FDA)-approved drugs for the treatment of COVID-19, although several antiviral drugs are available for repurposing. Many of these drugs suffer from polymorphic transformations with changes in the drug’s safety and efficacy; many are...
Main Authors: | Julia L. Shamshina, Robin D. Rogers |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-08-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/17/6002 |
Similar Items
-
Enhanced In Vitro Antiviral Activity of Hydroxychloroquine Ionic Liquids against SARS-CoV-2
by: Francisco Faísca, et al.
Published: (2022-04-01) -
Drug‑Drug and Drug‑Nutraceutical Cocrystal/Salt as Alternative Medicine for Combination Therapy: A Crystal Engineering Approach
by: Ranjit Thakuria, et al.
Published: (2018-02-01) -
Pharmaceutical Cocrystals—A Review
by: Sheetal S. Buddhadev, et al.
Published: (2021-03-01) -
Exploration of various solid forms of novel (1H-Benzimidazole, 2-[4-(1,1-dimethylethyl) phenyl])
by: Smruti Rekha Rout, et al.
Published: (2023-01-01) -
Antimicrobial Activities of Highly Bioavailable Organic Salts and Ionic Liquids from Fluoroquinolones
by: Miguel M. Santos, et al.
Published: (2020-07-01)